Decreased Striatal RGS2 Expression Is Neuroprotective in Huntington's Disease (HD) and Exemplifies a Compensatory Aspect of HD-Induced Gene Regulation
Open Access
- 14 July 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (7) , e22231
Abstract
The molecular phenotype of Huntington's disease (HD) is known to comprise highly reproducible changes in gene expression involving striatal signaling genes. Here we test whether individual changes in striatal gene expression are capable of mitigating HD-related neurotoxicity. We used protein-encoding and shRNA-expressing lentiviral vectors to evaluate the effects of RGS2, RASD2, STEP and NNAT downregulation in HD. Of these four genes, only RGS2 and RASD2 modified mutant htt fragment toxicity in cultured rat primary striatal neurons. In both cases, disease modulation was in the opposite of the predicted direction: whereas decreased expression of RGS2 and RASD2 was associated with the HD condition, restoring expression enhanced degeneration of striatal cells. Conversely, silencing of RGS2 or RASD2 enhanced disease-related changes in gene expression and resulted in significant neuroprotection. These results indicate that RGS2 and RASD2 downregulation comprises a compensatory response that allows neurons to better tolerate huntingtin toxicity. Assessment of the possible mechanism of RGS2-mediated neuroprotection showed that RGS2 downregulation enhanced ERK activation. These results establish a novel link between the inhibition of RGS2 and neuroprotective modulation of ERK activity. Our findings both identify RGS2 downregulation as a novel compensatory response in HD neurons and suggest that RGS2 inhibition might be considered as an innovative target for neuroprotective drug development.Keywords
This publication has 54 references indexed in Scilit:
- CRTC3 links catecholamine signalling to energy balanceNature, 2010
- ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's diseaseHuman Molecular Genetics, 2010
- CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's diseaseHuman Molecular Genetics, 2010
- Rhes, a Striatal Specific Protein, Mediates Mutant-Huntingtin CytotoxicityScience, 2009
- The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic miceProceedings of the National Academy of Sciences, 2008
- Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's diseaseProgress in Neurobiology, 2007
- Rhes Is Involved in Striatal FunctionMolecular and Cellular Biology, 2004
- NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signalingNature Neuroscience, 2002
- Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in BrainScience, 1997
- Molecular Cloning of a Novel mRNA (Neuronatin) That Is Highly Expressed in Neonatal Mammalian BrainBiochemical and Biophysical Research Communications, 1994